drugset / Trial / NCT01210183

Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose

NCT01210183

Phase 2/3 Completed 6 enrolled Universidad Nacional de Rosario
NaSingle-groupSingle-blindTreatment

Summary

Dextrose injection in end-stage knee arthritis will cause growth of cartilage cells in a particular area of complete cartilage loss. Dextrose concentration will be 12.5%. Cartilage status will be monitored by pre and post treatment arthroscopy views with specialized (methylene blue) staining for cartilage.

Timeline

Start
2010-07
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextrose Unknown 9 ml Other
Subject Dextrose Unknown 12.5 % Other

Indications